Until 2020, no non-pharmacological intervention had ever been shown to lengthen telomeres in humans. Then a randomized controlled trial out of Tel Aviv University changed that. Hyperbaric oxygen therapy increased telomere length by 21.7% and decreased senescent T-cell populations by up to 37% — without medications, without lifestyle changes, without supplements. HBOT had reproduced, in a clinical trial, two of the cellular hallmarks of aging that longevity research has spent decades trying to target with drugs.
The Science: The Hyperoxic-Hypoxic Paradox
The mechanism behind HBOT’s longevity effects is counterintuitive. You might assume that exposing the body to high oxygen drives benefit through high oxygen alone. The reality is the opposite: it’s the fluctuation between hyperoxia (during the session) and relative hypoxia (when the session ends) that triggers the body’s regenerative response.
This is called the hyperoxic-hypoxic paradox, and it’s the same biological logic behind exercise: stress, then recovery, then adaptation.
When the brain perceives a sudden drop in oxygen after a hyperoxic session, it activates HIF-1α (hypoxia-inducible factor) and other regenerative pathways. Over a course of HBOT, this drives:
– Telomere extension in T helper cells (+21.7%) and B cells (+20%)
– Senescent cell clearance — up to 37% reduction in immunosenescent T cells
– Mitochondrial biogenesis — new, healthy mitochondria replacing dysfunctional ones
– Stem cell mobilization — 2x baseline after a single session, 8x after a course
– Angiogenesis — new capillary networks in tissues with chronic age-related underperfusion
– Cognitive improvement — measurable gains in attention, processing speed, and executive function in healthy 65+ adults
Each of these effects targets one or more of the recognized hallmarks of aging described in the influential López-Otín review.
The Landmark Studies
Three studies form the spine of the HBOT-and-aging literature:
### Hachmo et al., Aging (2020)
The headline study. 35 healthy adults over 64 received 60 sessions of HBOT at 2.0 ATA over 90 days. Results: T helper cell telomeres lengthened by over 20%; B cells showed the largest gain at 37.6%; senescent T-helper populations dropped by 37.3%. First demonstration in humans that a non-pharmacological intervention could move two hallmark aging biomarkers. First author is Hachmo; senior author is Hadanny — popular press often cites this as “Hadanny et al.” but the bibliographic record reads Hachmo.
### Hadanny et al., Aging (2020 — cognitive enhancement)
Cognitive aging study from the same Israeli group. 63 healthy adults over 64 received 60 sessions at 2.0 ATA. Results: significant gains in attention (effect size 0.745), processing speed (0.788), and executive function — confirmed by both neuropsychological testing and perfusion MRI imaging.
The Longevity Protocol
The longevity protocol differs from the brain-injury protocol primarily in volume.
### The Standard Longevity Protocol
– Pressure (clinical trials): 2.0 ATA — Hachmo 2020 telomere RCT and Hadanny 2020 cognitive enhancement RCT both used 2.0 ATA. No published longevity RCT has tested 1.5 ATA, so equivalent telomere or cognitive-aging endpoints at lower pressure are mechanism-inferred, not trial-confirmed.
– Pressure (home use, mechanism-inferred): Some users run 1.5 ATA home protocols at extended courses as a practical accommodation; readers should treat this as off-trial use rather than equivalent published evidence.
– Oxygen concentration: 100% (per the published trials)
– Session length: 90 minutes (per the published trials)
– Air breaks: 5-minute air break every 20 minutes of pure oxygen (this triggers the hyperoxic-hypoxic paradox)
– Cadence: 5 sessions per week
– Duration: 60 sessions, then maintenance 1–2 sessions per week
### The 60-Session Number
Why 60 sessions, not 40? Because telomere extension and senescent cell clearance are slow processes. The 40-session protocol that works for TBI captures most of the neurological recovery, but the cellular aging effects continue accruing through session 60.
### Maintenance After the Initial Course
Anecdotally, longevity-focused users transition to a 1–2 sessions-per-week maintenance schedule indefinitely after the initial 60-session course. The trial data on long-term maintenance is still developing, but the mechanistic case is strong: aging is continuous, so the intervention should be too.
The Cellular Mechanisms in More Detail
Beneath the headline biomarkers — telomeres, senescent cells, cognitive scores — sits a richer cellular picture worth understanding.
### Mitochondrial Renewal
Aging mitochondria accumulate damage and produce more reactive oxygen species (ROS) while generating less ATP. HBOT drives mitochondrial biogenesis — the creation of new, healthy mitochondria — through PGC-1α and related pathways. The result over a course of HBOT is a population of mitochondria that look and behave more like a younger person’s.
### Stem Cell Niches
The hematopoietic stem cell niche in bone marrow becomes less responsive with age. HBOT-driven nitric oxide signaling reactivates this niche, mobilizing CD34+ cells into circulation. These cells then home to tissues showing damage and contribute to repair — including in the brain, where neural progenitor activity normally declines steeply after age 50.
### Epigenetic Effects
While the headline 2020 telomere study did not measure DNA methylation, several follow-on analyses have suggested HBOT shifts the epigenetic age (Horvath clock) downward. Whether HBOT directly causes this or whether it’s downstream of the senescent cell clearance is still being resolved.
### Durability — what the trials actually report
The Hachmo 2020 telomere trial (PMID 33206062) measured outcomes at baseline and 1–2 weeks post-final-session; the Hadanny 2020 cognitive enhancement trial (PMID 32589613) reported outcomes at end-of-protocol only. Neither published abstract reports a long-term durability assessment for the longevity cohort specifically. The Hadanny 2024 follow-up (PMID 38360929) demonstrated 1-year durability of cognitive and sleep gains, but in a *Long COVID* cohort, not the longevity cohort. The mechanistic story — telomere lengthening and senescent-cell clearance are slow-decay biology — supports the inference that effects are not pharmacological dependencies that wash out, but the direct durability question for the longevity cohort remains open in the published literature.
Where Longevity HBOT Fits in a Complete Protocol
HBOT is most powerful in combination with other longevity inputs, not as a replacement for them. The longevity stack typically includes:
– Zone 2 cardio (3–4 sessions/week) — mitochondrial efficiency
– Resistance training (3–4 sessions/week) — preserves muscle mass and bone density
– Sleep optimization — non-negotiable for telomere maintenance
– Senolytic compounds (where appropriate) — clear senescent cells via a separate mechanism
– Time-restricted feeding — autophagy induction
– HBOT — the only intervention with documented telomere extension
Stacking these is synergistic, not redundant. HBOT and senolytics, for instance, both clear senescent cells but through entirely different mechanisms.
Hyperbaric oxygen therapy increases telomere length and decreases senescent cells in aging humans — without medications.
— Hachmo et al., Aging (2020)